간경변 환자의 관리
Management of Liver Cirrhosis
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
간경변증 환자의 예후는 유발원인, 간경변증의 심한 정도, 합병증의 정도 및 동반된 전신 질환 등 여러 가지 인자에 영향을 받는다. 간경변증의 합병증이 유발된 경우를 비대상성 간경변증이라고 하며 이들 합병증의 악화로 인해 이환율 및 사망률이 증가하게 된다. 간경변증의 진행을 억제하기 위한 치료와 함께 간경변증의 합병증의 발생을 예방하거나 적절한 치료를 함으로써 삶의 질과 생존율을 증가시킬 수 있다. 치료에 반응하지 않는 합병증을 가진 환자의 경우 예후가 불량하기 때문에 간이식을 고려하여야 한다.
Abstract
Liver cirrhosis has distortion of the hepatic architecture and the formation of regenerative nodules due to progressive hepatic fibrosis. Treatment of underlying etiology can slow or reverse the progression of liver fibrosis. Early stage is characterized by asymptomatic phase, termed ‘compensated cirrhosis’ follwed by the development of complications of portal hypertension and/or liver dysfunction, termed ‘decompensated cirrhosis’. The quality of life and survival of patients with cirrhosis can be improved by prevention and treatment of these complications. This review discuss the complication and its management in patients with liver cirrhosis.
참고문헌 (7)
- Giannini EG, "Platelet count", spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study, 2006, pp.101, 2511~2519
- Bañares R, "Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis", Hepatology, 35, pp.609~615 (2002)
- Bernard B, "Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis", Hepatology, 29, pp.1655~1661 (1999)
- Kim T, "Risk factors for hemorrhage from gastric fundal varices", Hepatology, 25, pp.307~312 (1997)
- Angeli P, "Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis", J Hepatol, 48(Suppl 1), pp.93~103 (2008)
- Sigal SH, "Restricted use of albumin for spontaneous bacterial peritonitis", Gut, 56, pp.597~599 (2007)
- Mas A, "Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial", J Hepatol, 38, pp.51~58 (2003)